Scilex acquires rights to ELYXYB in the U.S. and Canada for acute treatment of migraine

Scilex, a majority-owned subsidiary of Sorrento Therapeutics, has acquired rights to ELYXYB (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

“I am delighted that liquid celecoxib will remain on the market. It is a very important medication we use to treat migraine, with fast onset and favorable safety and tolerability profile,” said Dr. Peter McAllister, medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research and Ki Clinical Research, associate professor of Neurology at the Yale University School of Medicine, New Haven, Connecticut, and clinical professor of Neurology and Anatomy at the Frank H. Netter School of Medicine at Quinnipiac University, Hamden, Connecticut.

“The acquisition of ELYXYB reaffirms Scilex’s commitment to offer innovative, non-opioid pain management products and to develop meaningfully differentiated programs that address significant unmet needs leading to better health outcomes for the millions of acute and chronic pain patients,” said Henry Ji, Ph.D., executive chairperson of Scilex and chairman and Chief Executive Officer of Sorrento.

“We are very pleased to announce the addition of ELYXYB to our current portfolio of two FDA-approved commercial non-opioid pain products. We expect this third product will accelerate our strong commitment to offer novel formulations that are opioid sparing and non-addictive for millions of acute and chronic pain patients and will be a great fit within our top-notch commercial team,” said Jaisim Shah, president and Chief Executive Officer of Scilex.

ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption. In pivotal studies, ELYXYB demonstrated a rapid onset of action which is critically important to patients suffering from acute migraine attacks.

The results from pivotal studies with ELYXYB have established the efficacy of celecoxib in the treatment of migraine with very few adverse events. This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a conventional oral solid dosage form. For adult patients who suffer from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options.  ELYXYB’s unit-dose of oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news